Neutral sphingomyelinase 2 (nSMase2) has gained increasing attention as a therapeutic target to regulate ceramide production in various disease conditions. Phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)-pyrrolidin-3-yl)carbamate (PDDC) is a submicromolar nSMase2 inhibitor and has been widely used to study the pharmacological effects of nSMase2 inhibition. Through screening of compounds containing a bicyclic 5-6 fused ring, larotrectinib containing a pyrazolo[1,5-a]pyrimidine ring was identified as a low micromolar inhibitor of nSMase2. This prompted us to investigate the pyrazolo[1,5-a]pyrimidin-3-amine ring as a novel scaffold to replace the imidazo[1,2-b]pyridazine-8-amine ring of PDDC. A series of molecules containing a pyrazolo[1,5-a]pyrimidin-3-amine ring were synthesized and tested for their ability to inhibit human nSMase2. Several compounds exhibited nSMase2 inhibitory potency superior to that of PDDC. Among these, N,N-dimethyl-5-morpholinopyrazolo[1,5-a]pyrimidin-3-amine (11j) was found to be metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio, demonstrating the potential of pyrazolo[1,5-a]pyrimidine ring as an effective scaffold for nSMase2 inhibition.

Johns Hopkins Drug Discovery United States

Johns Hopkins Drug Discovery United States; Department of Neurology United States

Johns Hopkins Drug Discovery United States; Department of Neurology United States; Department of Pharmacology and Molecular Sciences Johns Hopkins School of Medicine Baltimore MD 21205 United States

Johns Hopkins Drug Discovery United States; Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic 5 v i Prague 166 00 Czech Republic

Johns Hopkins Drug Discovery United States; Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic 5 v i Prague 166 00 Czech Republic; Department of Organic Chemistry Charles University Prague 128 00 Czech Republic

Zobrazit více v PubMed

Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W, Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling?, Proc Natl Acad Sci U S A, 95 (1998) 3638–3643. PubMed PMC

Hofmann K, Tomiuk S, Wolff G, Stoffel W, Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase, Proc Natl Acad Sci U S A, 97 (2000) 5895–5900. PubMed PMC

Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Kronke M, Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein, J Biol Chem, 281 (2006) 13784–13793. PubMed

Wu BX, Rajagopalan V, Roddy PL, Clarke CJ, Hannun YA, Identification and characterization of murine mitochondria-associated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5, J Biol Chem, 285 (2010) 17993–18002. PubMed PMC

Wu BX, Clarke CJ, Hannun YA, Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses, Neuromolecular Med, 12 (2010) 320–330. PubMed PMC

Tallon C, Hollinger KR, Pal A, Bell BJ, Rais R, Tsukamoto T, Witwer KW, Haughey NJ, Slusher BS, Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases, Drug Discov Today, 26 (2021) 1656–1668. PubMed PMC

Skacel J, Slusher BS, Tsukamoto T, Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network, J Med Chem, 64 (2021) 279–297. PubMed PMC

Rojas C, Barnaeva E, Thomas AG, Hu X, Southall N, Marugan J, Chaudhuri AD, Yoo SW, Hin N, Stepanek O, Wu Y, Zimmermann SC, Gadiano AG, Tsukamoto T, Rais R, Haughey N, Ferrer M, Slusher BS, DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation, Sci Rep, 8 (2018) 17715. PubMed PMC

Stepanek O, Hin N, Thomas AG, Dash RP, Alt J, Rais R, Rojas C, Slusher BS, Tsukamoto T, Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold, Eur J Med Chem, 170 (2019) 276–289. PubMed PMC

Rojas C, Sala M, Thomas AG, Datta Chaudhuri A, Yoo SW, Li Z, Dash RP, Rais R, Haughey NJ, Nencka R, Slusher B, A novel and potent brain penetrant inhibitor of extracellular vesicle release, Br J Pharmacol, 176 (2019) 3857–3870. PubMed PMC

Sala M, Hollinger KR, Thomas AG, Dash RP, Tallon C, Veeravalli V, Lovell L, Kogler M, Hrebabecky H, Prochazkova E, Nesuta O, Donoghue A, Lam J, Rais R, Rojas C, Slusher BS, Nencka R, Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer’s Disease, J Med Chem, 63 (2020) 6028–6056. PubMed PMC

Bilousova T, Simmons BJ, Knapp RR, Elias CJ, Campagna J, Melnik M, Chandra S, Focht S, Zhu C, Vadivel K, Jagodzinska B, Cohn W, Spilman P, Gylys KH, Garg NK, John V, Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease, ACS Chem. Biol, 15 (2020) 1671–1684. PubMed PMC

Tallon C, Picciolini S, Yoo SW, Thomas AG, Pal A, Alt J, Carlomagno C, Gualerzi A, Rais R, Haughey NJ, Bedoni M, Slusher BS, Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury, Biochem Pharmacol, 194 (2021) 114796. PubMed PMC

Zhu X, Hollinger KR, Huang Y, Borjabad A, Kim BH, Arab T, Thomas AG, Moniruzzaman M, Lovell L, Turchinovich A, Witwer KW, Volsky DJ, Haughey NJ, Slusher BS, Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV, Neurobiol Dis, 169 (2022) 105734. PubMed PMC

Chi L.-l., Hao L.-l., Cai Z.-q., Kong D.-l., Wang Y.-n., Qin W.-t., Gao Y, Qu Z.-z., Design, Synthesis, and Biological Evaluation of Novel Pyrazolo[1,5-a]pyrimidine and 1,3-Benzodiazine Derivatives as Potent Antitumor Agents, Russian Journal of General Chemistry, 92 (2022) 2698–2707.

Lv X, Zheng Y, Pan J, Chen L, Lin K, Ye D, Zhou W, Assignment of NMR data and Conformational analysis of larotrectinib and its precursors, Tetrahedron, 85 (2021) 132064.

Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, Bandaru VV, Yoo SW, Westwood NJ, Rogers GW, McArthur JC, Haughey NJ, Slusher BS, Rojas C, Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties, PLoS One, 10 (2015) e0124481. PubMed PMC

Iorkula TH, Tolman BA, Singleton JD, Peterson MA, An efficient microwave assisted copper catalyzed C-3 amination of 3-bromopyrazolo[1,5-a]pyrimidine, Tetrahedron Letters, 118 (2023) 154393.

Giancola JB, Bonifazi A, Cao J, Ku T, Haraczy AJ, Lam J, Rais R, Coggiano MA, Tanda G, Newman AH, Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability, Eur J Med Chem, 208 (2020) 112674. PubMed PMC

Zhou L, Yang L, Tilton S, Wang J, Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery, J Pharm Sci, 96 (2007) 3052–3071. PubMed